Shuttle Pharma Announces Phase 2 Clinical Trial Of Ropidoxuridine For Glioblastoma Now Open For Enrollment At Two Sites, Receives FDA Orphan Drug Designation, And Regains Nasdaq Compliance After Filing Delayed Financial Reports
Shuttle Pharma Announces Phase 2 Clinical Trial Of Ropidoxuridine For Glioblastoma Now Open For Enrollment At Two Sites, Receives FDA Orphan Drug Designation, And Regains Nasdaq Compliance After Filing Delayed Financial Reports
Shuttle Pharma宣佈Ropidoxuridine用於膠質母細胞瘤的2期臨床試驗現已在兩個地點開放招募，獲得FDA孤兒藥物認證，並在提交財務報表延遲後恢復納斯達克合規性。
Shuttle Pharma Announces Phase 2 Clinical Trial Of Ropidoxuridine For Glioblastoma Now Open For Enrollment At Two Sites, Receives FDA Orphan Drug Designation, And Regains Nasdaq Compliance After Filing Delayed Financial Reports
Shuttle Pharma宣佈Ropidoxuridine用於膠質母細胞瘤的2期臨床試驗現已在兩個地點開放招募，獲得FDA孤兒藥物認證，並在提交財務報表延遲後恢復納斯達克合規性。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間